347 related articles for article (PubMed ID: 21813069)
1. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
[No Abstract] [Full Text] [Related]
2. Adalimumab for sight-threatening uveitis in Behçet's disease.
Mushtaq B; Saeed T; Situnayake RD; Murray PI
Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
[TBL] [Abstract][Full Text] [Related]
3. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
Interlandi E; Leccese P; Olivieri I; Latanza L
Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
6. Acquired resistance to infliximab against uveitis due to Behçet's disease after one year of administration.
Ito T; Sonoda KH; Hijioka K; Fujimoto T; Ishibashi T
Jpn J Ophthalmol; 2010 Sep; 54(5):502-4. PubMed ID: 21052918
[No Abstract] [Full Text] [Related]
7. Clinical experience with adalimumab in the treatment of ocular Behçet disease.
Bawazeer A; Raffa LH; Nizamuddin SH
Ocul Immunol Inflamm; 2010 Jun; 18(3):226-32. PubMed ID: 20482404
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of infliximab on the acute attack of uveitis.
Alokaily F; Alsaleh S; Al-Balawi M; Al-Rashidi S
Saudi Med J; 2010 Jan; 31(1):82-5. PubMed ID: 20062906
[TBL] [Abstract][Full Text] [Related]
9. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
[No Abstract] [Full Text] [Related]
10. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.
Belzunegui J; López L; Paniagua I; Intxausti JJ; Maíz O
Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S133-4. PubMed ID: 19026138
[No Abstract] [Full Text] [Related]
11. [Infliximab treatment for Behçet's disease--beginning of the biological drug era].
Namba K
Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):85-6. PubMed ID: 20187504
[No Abstract] [Full Text] [Related]
12. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis.
Takase K; Ohno S; Ideguchi H; Uchio E; Takeno M; Ishigatsubo Y
Rheumatol Int; 2011 Feb; 31(2):243-5. PubMed ID: 19816689
[TBL] [Abstract][Full Text] [Related]
13. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
Morris DS; Gavin MP; Sturrock RD
Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
[No Abstract] [Full Text] [Related]
14. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy.
Ariyachaipanich A; Berkelhammer C; Nicola H
Inflamm Bowel Dis; 2009 Dec; 15(12):1769-71. PubMed ID: 19177427
[No Abstract] [Full Text] [Related]
15. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab.
Olivieri I; Leccese P; D'Angelo S; Padula A; Nigro A; Palazzi C; Coniglio G; Latanza L
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S54-7. PubMed ID: 21968237
[TBL] [Abstract][Full Text] [Related]
16. [Behcet's refractory uveitis treated successfully by infliximab].
Mahfoudhi M; Hariz A; Ben Abdelghani K; Turki S; Kheder A
Tunis Med; 2014 Jan; 92(1):41-2. PubMed ID: 24879172
[No Abstract] [Full Text] [Related]
17. Induction of regulatory T cells by infliximab in Behcet's disease.
Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab in severe and refractory non-infectious uveitis.
Papo M; Bielefeld P; Vallet H; Seve P; Wechsler B; Cacoub P; Le Hoang P; Papo T; Bodaghi B; Saadoun D
Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S75-9. PubMed ID: 25268663
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.
Olivieri I; D' Angelo S; Padula A; Leccese P; Mennillo GA
Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S112. PubMed ID: 19796550
[No Abstract] [Full Text] [Related]
20. Effect of infliximab on refractory uveitis in Behcet's disease.
Sayarlioglu M; Cinal A; Topcu N; Demirok A
Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
[No Abstract] [Full Text] [Related]
[Next] [New Search]
